Stockscreener 앱 받기
63.68
0.87%
0.4837
Astrazeneca PLC 주식(AZN)의 최신 뉴스
AstraZeneca, Merck Add New Patent to Campaign on Lynparza Copies - Bloomberg Law
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns - Benzinga
CEO & Executive Director of AstraZeneca Picks Up 9.9% More Stock - Simply Wall St
Primecap Management Co. CA Trims Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now - The Motley Fool
astrazeneca non-executive director buys company shares By Investing.com - Investing.com Nigeria
How AstraZeneca Ruling Could Change Dosage Patent Claims - Law360
Claim Spotter: AstraZeneca calls in Fieldfisher over HQ fire - The Lawyer
AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch
AstraZeneca, United Utilities, AFC Energy: What brokers said today, - Proactive Investors UK
AstraZeneca raised to neutral at UBS despite China headwinds - MSN
AstraZeneca stock raised to neutral at UBS (AZN:NASDAQ) - Seeking Alpha
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
AstraZeneca Says Current, Former Executives Involved in China Probe - MSN
Jennison Associates LLC Sells 2,059,108 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Howe & Rusling Inc. Sells 29,784 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time - Pharmaceutical Technology
AstraZeneca Loses Lone Bear as UBS Upgrades After China-Led Rout - Bloomberg
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Boosted by Pathstone Holdings LLC - MarketBeat
AstraZeneca upgraded by leading investment bank, but challenges remainhere's why - Proactive Investors UK
AstraZeneca: UBS is no longer a seller - Marketscreener.com
AstraZeneca hits out at NICE block to breast cancer drug - Proactive Investors UK
AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview - Citeline News & Insights
AstraZeneca PLC ADR rises Tuesday, still underperforms market - MarketWatch
AstraZeneca rises Tuesday, outperforms market - MarketWatch
Trump-induced Pharma fears shouldn't be long-lived - Marketscreener.com
AstraZeneca (AZN) Faces Legal Scrutiny Amid Chinese Investigatio - GuruFocus.com
New Millennium Group LLC Sells 28,749 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC - Yahoo Finance
Prospera Financial Services Inc Boosts Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Leerink Partnrs Cuts Earnings Estimates for AstraZeneca - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Bought by Sumitomo Mitsui Trust Group Inc. - MarketBeat
CHMP recommends AstraZeneca’s Tagrisso for EU approval for NSCLC - Pharmaceutical Technology
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca - Korea Economic Daily
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLCAZN - PR Newswire
Stocks in news: Waaree Energies, GMR Infra, AstraZeneca, Indus Towers, Ashoka Buildcon & ITI - Business Today
AstraZeneca Tries Plan B For Dato-DXd After Regulator Feedback - Citeline News & Insights
AstraZeneca PLC ADR rises Monday, still underperforms market - MarketWatch
AstraZeneca falls Monday, underperforms market - MarketWatch
Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership - Pharmaceutical Technology
Astrazeneca exercises option for type 1 diabetes Treg cell therapy program with Quell - BioWorld Online
Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
Is AstraZeneca PLC (AZN) A Cheap NASDAQ Stock To Invest In Now? - Insider Monkey
AstraZeneca's Tagrisso recommended for EU approval - ShareCast
AstraZeneca: new positive CHMP opinion for Tagrisso - Marketscreener.com
AstraZeneca's cell lung cancer drug sent for EU approval - baha news
Natixis Advisors LLC Acquires 117,162 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Sees Large Increase in Short Interest - MarketBeat
AstraZeneca PLC (LON:AZN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
AstraZeneca PLC ADR outperforms competitors despite losses on the day - MarketWatch
FIVE at FIVE: GSK, AstraZeneca plummet; LandSec profits; Economy stalls; FTSE 100 meanders; TT snubs Volex - Proactive Investors USA
AstraZeneca PLC (LON:AZN) Insider Pascal Soriot Purchases 20,000 Shares - MarketBeat
Trump anti-vax health appointment wipes £7bn from AstraZeneca and GSK - Proactive Investors USA
FTSE 100 Live: Index regains; GSK, AstraZeneca weighUK economic growth slows - Proactive Investors UK
AstraZeneca rises Thursday, outperforms market - MarketWatch
July 2025 Options Now Available For AstraZeneca (AZN) - Nasdaq
Is AstraZeneca a Buy as It Eyes the Weight Loss Market? - The Motley Fool
AstraZeneca talks up US growth as China problems fester - The Boston Globe
AstraZeneca Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Simply Wall St
China has trapped the tiger of AstraZeneca’s growth - Financial Times
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity (NASDAQ:AZN) - Seeking Alpha
AstraZeneca PLC ADR rises Wednesday, outperforms market - MarketWatch
AstraZeneca pledges $3.5bn to biopharma research and manufacturing - BioProcess Insider
MSD and AstraZeneca report positive topline data from Koselugo trial for NF1 - Clinical Trials Arena
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus.com
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call Transcript - MSN
자본화:
|
볼륨(24시간):